News Touchdown for Rocket as its first gene therapy gets US okay Rocket Pharma has won FDA approval for the first gene therapy for LAD-I, a devastating genetic disorder causing severe vulnerability to infections.
News Corcept gets FDA OK for first-in-class ovarian cancer drug Corcept shares surge on FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.
News FDA clears Denali's 'game-changer' Hunter syndrome drug Denali's Avlayah is the first drug for neurological complications associated Hunter syndrome to be approved in the US.
News Anavex sinks after pulling Alzheimer's filing in EU Shares in Anavex Life Sciences lost more than a third of their value today after the company abandoned an EU filing for its Alzheimer's therapy.
News Grifols board backs IPO for US business Spanish plasma medicine specialist Grifols is planning to sell a minority stake in its US business, via an IPO, to help pay down its debt.
News Keytruda cleared for NHS use in early head and neck cancer MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer.
News Where others missed, AZ's IL-33 drug hits the mark in COPD AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.